|
|
Article: Requip improves symptoms of restless legs syndrome at 1 week, studies show.
- Article from:
- Biotech Week
- Article date:
- July 7, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 JUL 7 - (NewsRx.com & NewsRx.net) -- More than a third of patients taking GlaxoSmithKline's Requip (ropinirole HCl) for restless legs syndrome (RLS) in clinical trials experienced significant improvement in their symptoms at 1 week, according to the results presented at the Associated Professional Sleep Societies 18th Annual Meeting in Philadelphia, Pennsylvania.
The results were from combined data from three double-blind, placebo-controlled trials of Requip in RLS, which included 618 patients, ages 18 to 79 years. Requip is under review by the U.S. Food and Drug Administration (FDA) for the treatment of RLS. There is no currently approved treatment for RLS ...